mr coordinating committee
play

MR Coordinating Committee Mark Rosen, MD PhD May 16, 2018 Topics - PDF document

5/16/2018 MR Coordinating Committee Mark Rosen, MD PhD May 16, 2018 Topics of Discussion Change in composition of BCs and TFs; role of MR CC 1 5/16/2018 Meta-analysis Performed New BCs created from legacy PDF Meta-analysis Performed 2


  1. 5/16/2018 MR Coordinating Committee Mark Rosen, MD PhD May 16, 2018 Topics of Discussion • Change in composition of BCs and TFs; role of MR CC 1

  2. 5/16/2018 Meta-analysis Performed New BCs created from legacy PDF Meta-analysis Performed 2

  3. 5/16/2018 Augment MR CC… Leverage Areas of Specialization within MR CC “Whole Body” metrics Brain metrics Joint/MSK metrics Liver metrics Meta-analysis Performed Topics of Discussion • Change in composition of BCs and TFs; role of MR CC • Plans for progression of BC activity beyond profiles 3

  4. 5/16/2018 Progressing to Profiles…and Beyond Meta-analysis Performed …stopping point of some BC activity prior to claim/clinical confirmation Topics of Discussion • Change in composition of BCs and TFs; role of MR CC • Plans for progression of BC activity beyond profiles • Challenges in anatomic specific vs. generic measurands 4

  5. 5/16/2018 DWI: brain claim DWI: liver claim “Whole Body” metrics Brain metrics DWI: prostate claim Joint/MSK metrics Liver metrics Meta-analysis Performed Topics of Discussion • Change in composition of BCs and TFs; role of MR CC • Plans for progression of BC activity beyond profiles • Challenges in anatomic specific vs. generic measurands • New biomarkers in MR? • Biomarkers vs. Phenotypes? • Multi-measurand imaging protocols (e.g liver, prostate, brain) • Role of radiomics 5

  6. 5/16/2018 CV T1  CV K trans “Whole Body” metrics Brain metrics fMRI(motor/language)  Resting state fMRI Joint/MSK metrics CV T2*  CV PDFF Liver metrics Meta-analysis Performed Topics of Discussion • Change in composition of BCs and TFs; role of MR CC • Plans for progression of BC activity beyond profiles • Challenges in anatomic specific vs. generic measurands • New biomarkers in MR? • Biomarkers vs. Phenotypes? • Multi-measurand imaging protocols (e.g liver, prostate, brain) • Role of radiomics • Adapting profiles for technological advancements in MR 6

  7. 5/16/2018 Profiles v2.0 in MR • DCE: re-evaluate claims for modern imaging • 3T and B1 heterogeneity • Groundwork project  challenge of B1 compensation • Effect of FOV: brain vs body imaging • Vendor-specific differences in B1 mapping protocols •  strong effect on VFA correlations Profiles v2.0 in MR • Next generation of MR imaging • Multi-band excitation/parallel imaging/etc. • Need to recreate claim generation process (“from scratch”?) • Metrology concern: “bias creep” in using last methodology as new ground truth • Liver examples: MRE and PDFF become the “gold standard” • FDA example: leveraging prior knowledge? 7

  8. 5/16/2018 8

Recommend


More recommend